Crinetics Pharmaceuticals, Inc.
CRNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4,130,435 | $2,066,166 | $951,271 | $1,091,967 |
| - Cash | $264,545 | $54,897 | $32,672 | $200,695 |
| + Debt | $51,722 | $51,728 | $3,075 | $3,074 |
| Enterprise Value | $3,917,612 | $2,062,997 | $921,674 | $894,346 |
| Revenue | $1,039 | $4,013 | $4,737 | $1,078 |
| % Growth | -74.1% | -15.3% | 339.4% | – |
| Gross Profit | -$1,746 | $4,013 | $4,737 | $1,078 |
| % Margin | -168% | 100% | 100% | 100% |
| EBITDA | -$336,069 | -$221,510 | -$166,899 | -$106,780 |
| % Margin | -32,345.4% | -5,519.8% | -3,523.3% | -9,905.4% |
| Net Income | -$298,408 | -$214,529 | -$163,918 | -$107,641 |
| % Margin | -28,720.7% | -5,345.9% | -3,460.4% | -9,985.3% |
| EPS Diluted | -3.69 | -3.69 | -3.15 | -2.8 |
| % Growth | 0% | -17.1% | -12.5% | – |
| Operating Cash Flow | -$225,970 | -$166,307 | -$115,205 | -$88,588 |
| Capital Expenditures | -$3,844 | -$4,688 | -$1,656 | -$436 |
| Free Cash Flow | -$229,814 | -$170,995 | -$116,861 | -$89,024 |